The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

Investigational New Drugs

Volumn 21, Issue 3, 2003, Pages 259-268

  Kraus, Lisa Ann ^a,c   Samuel, Shanti K ^a   Schmid, Steven M ^a   Dykes, Donald J ^a   Waud, William R ^a   Bissery, Marie Christine ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b SANOFI   (France)

^c BIOGEN   (United States)

Author keywords

bcl 2; Docetaxel; Taxotere ; Xenografts

Indexed keywords

DOCETAXEL; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0344420184     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025436307913     Document Type: Article

References (49)

1. Denis JN, Greene AE, Guenard D, Gueritte-Voegelein F, Mangatal L, Potier P: A highly efficient, practical approach to natural taxol. J Am Chem Soc 110: 5917-5919, 1988
2. Mangatal L, Adeline MT, Guenard D, Gueritte-Voegelein F, Potier, P: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 45: 4177-4190, 1989
3. Garcia P, Braguer D, Carles G, el Khyari S, Barra Y, de Ines C, Barasoain I, Briand C: Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother Pharmacol 34: 335-343, 1994
4. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22: 3-16, 1995
5. Stein CA: Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26: 3-7, 1999
6. Pienta KJ: Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 28: 3-7, 2001
7. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991
8. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F: Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6: 339-8, 1995
9. Dykes DJ, Bissery MC, Harrison SD, Waud WR: Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs 13: 1-11, 1995
10. Friedland D, Cohen J, Miller R, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of bcl-2. Semin Oncol 26: 19-23, 1999
11. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26: 14-18, 1999
12. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10: 33-38, 1999
13. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17: 958-967, 1999
14. Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995
15. Haldar S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996
16. Haldar S, Basu A, Croce CM: bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997
17. Nehme A, Varadarajan P, Sellakumar G, Gerhold M, Niedner H, Zhang Q, Lin X, Christen RD: Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. Br J Cancer 84: 1571-1576, 2001
18. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541-546, 1995
19. Reed JC: bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34: 9-19, 1997
20. Schmitt E, Sane AT, Steyaert A, Cimoli G, Bertrand R: The bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation. Biochem Cell Biol 75: 301-314, 1997
21. Haldar S, Jena N, DuBois GC, Takayama S, Reed JC, Fu SS, Croce CM: Purification and characterization of the bcl-2 protein. Arch Biochem Biophys 315: 483-488, 1994
22. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-323, 1994
23. Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411, 1992
24. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4: 71-79, 1994
25. Pepper C, Bentley P, Hoy T: Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 95: 513-517, 1996
26. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995
27. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP: bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55: 2576-2582, 1995
28. Fang W, Rivard JJ, Ganser JA, LeBien TW, Nath KA, Mueller DL, Behrens TW: bcl-xL rescues WEHI 231 B lymphocytes from oxidant-mediated death following diverse apoptotic stimuli. J Immunol 155: 66-75, 1995
29. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA: bcl-xL in prostate cancer cells: effects of overexpression and downregulation on chemosensitivity. Cancer Res 60: 6052-6060, 2000
30. Costa A, Licitra L, Veneroni S, Daidone MG, Grandi C, Cavina R, Molinari R, Silvestrini R: Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer 79: 619-623, 1998
31. Guinan P, Didomenico D, Brown J, Shaw M, Sharifi R, Ray V, Shott S, Rubenstein M: The effect of androgen deprivation on malignant and benign prostate tissue. Med Oncol 14: 145-152, 1997
32. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87: 265-272, 1996
33. Hogarth LA, Hall AG: Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 93: 2671-2678, 1999
34. Logsdon MD, Meyn RE, Besa PC, Pugh WC, Stephens LC, Peters LJ, Milas L, Cox JD, Cabanillas F, Brisbay S, Andersen M, McDonnell TJ: Apoptosis and the bcl-2 gene family - patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 44: 19-29, 1999
35. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600, 1997
36. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H, Einhom S: Response to interferon therapy in patients with multiple myeloma correlates with expression of the bcl-2 oncoprotein. Int J Cancer 63: 190-192, 1995
37. De Cesare M, Pratesi G, Giusti A, Polizzi D, Zunino F: Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts. Br J Cancer 77: 434-439, 1998
38. Tang DG, Li L, Chopra DP, Porter AT: Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 58: 3466-3479, 1998
39. Van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH: Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 35: 664-671, 1999
40. Griswold DP, Schabel FM, Wilcox WS, Simpson-Herren L, Skipper HE: Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. Cancer Chemother Rep 52: 345-387, 1968
41. Veis DJ, Sentman CL, Bach EA, Korsmeyer SJ: Expression of the bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol 151: 2546-2554, 1993
42. Dean PN, Jett JH: Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol 60: 523-527, 1974
43. Marquardt DW: An algorithm for least-squares estimation of nonlinear parameters. Appl Math 11: 431-441, 1963
44. Pantazis P, Chatterjee D, Wyche J, DeJesus A, Early J, Plaschke S, Giovanella B: Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins. J Exp Ther Oncol 1: 322-333, 1996
45. Pratesi G, Polizzi D, Perego P, Dal Bo L, Zunino F: bcl-2 phosphorylation in a human breast carcinoma xenograft: a common event in response to effective DNA-damaging drugs. Biochem Pharmacol 60: 77-82, 2000
46. Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L: Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 43: 165-172, 1999
47. Veitia R, Bissery MC, Martinez C, Fellous A: Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 78: 871-877, 1998
48. Van Oosterom AT: Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol 22: 22-28, 1995
49. Shirahama T, Sakakura C, Sweeney EA, Ozawa M, Takemoto M, Nishiyama K, Ohi Y, Igarashi Y: Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-X(L) gene expression. FEBS Lett 407: 97-100, 1997